Assuming optimization of patient outcomes, rather than cost, is the primary driver governing use of PCSK9 inhibitors, which patients in a medical cardiology practice would you single out for this therapy, and to achieve what LDL-C target levels?

Name: Assuming optimization of patient outcomes, rather than cost, is the primary driver governing use of PCSK9 inhibitors, which patients in a medical cardiology practice would you single out for this therapy, and to achieve what LDL-C target levels?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Robert Rosenson, MD

Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart Institute
New York, NY